The FDA has granted Fast Track designation to Nacuity Pharmaceuticals' NPI-001 (N-acetylcysteine amide) tablets for retinitis pigmentosa (RP) treatment.
The Usher Syndrome market is poised for growth with emerging therapies addressing the root cause of the disease, offering alternatives to supportive care.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.